Genmab — Maj 2025

[E_L]

Endometrial cancer data on Genmab’s Elahere rival beat forecast, fuelling push into phase 3 https://www.fiercebiotech.com/biotech/endometrial-cancer-data-genmabs-elahere-rival-beat-forecast-fuelling-push-phase-3

[Solsen]

Yes I belive Rina-S could be the expectation to a multiblockbuster drug that will change the trend for Genmab.

[bikube]

Jeg får hver dag "BØRS EXTRA" fra Norge. Den udsendes om morgenen før børsåbning til abonnenter, men der er jeg for nærig, så jeg få den over middag. Der står det i, så deres abonn
enter var informeret før børsen åbnede.

[M_T_A]

Nogen der har nyt om Abbvies søgsmål mod Genmab siden det kom frem?

[gentogen]

Næ. Det må være lidt op ad bakke at bevise, at man har en dyb hemmelighed, som konkurrenter burde kende alt til....

[gentogen]

Enig Solsen. Selv om Genmabs situation er noget speciel, så hjælper det med 100% ejerskab og 50% ejerskab, når man regner lidt på mulige fremtider...

[E_L]

ASCO25: Genmab's ex-Profound ADC continues to prove mettle in gynecological cancers https://firstwordpharma.com/story/5965833

[E_L]

@M_T_A here you can monitor a bit what is happening, but this will probably take a long time, i don't expect to hear any news for the next year...
https://www.pacermonitor.com/public/case/57357486/AbbVie_Inc_v_Genmab_AS_et_al

[E_L]

Die AbbVie-Aktie könnte bald neuen Rückenwind aus dem Onkologie-Portfolio erhalten. Denn Partner Genmab präsentiert auf der diesjährigen ASCO-Konferenz bahnbrechende Langzeitdaten zu Epcoritamab https://www.aktiencheck.de/news/Artikel-AbbVie_Aktie_Beeindruckende_Ertragserhoehung-18589388

[E_L]

Shicheng Guo
@ShihchengGuo
New from Stanford & Genmab: UniTox uses GPT-4o to extract drug-induced toxicities from 2,400+ FDA labels into a structured dataset. https://x.com/ShihchengGuo/status/1926138781318385917

[E_L]

a bit more on - Insourcing Cell-line Development Streamlines Antibody Biomanufacturing - https://www.genengnews.com/topics/bioprocessing/insourcing-cell-line-development-streamlines-antibody-biomanufacturing

[M_T_A]

@EL thank you so much.

[ProinvestorNEWS]

Genmabs fremtidige salg af epcoritamab https://proinvestor.com/boards/126539

[E_L]

GEN1057 moves expected completion dates a year earlier, never really know what it means; either recruitment is going superfast or patients can stay on the drug much shorter as anticipated... anyway, we'll know earlier https://clinicaltrials.gov/study/NCT06573294?tab=history&a=7&b=8#version-content-panel

[gentogen]

As the 1057 study is a small phase 1 FIH study the goal is not to look at long term data so in a sense only positive if they can reach conclusions a bit sooner, I guess

[gentogen]

It would be nice i their laser sharp focus for once would be positive...

[Sukkeralf]

Do we know if all patients have been enrolled?

[E_L]

probably
not yet; the status is still 'recruiting' and 2 recruitment centers were just added

[Solsen]

Abbvie arbejder med nye payloads med bedre virkning deres allerede godkendte EMRELIS (telisotuzumab vedotin-tllv). Nyt stof ABBV-
400 (Telisotuzumab adizutecan) er værd at følge https://news.abbvie.com/2025-05-27-AbbVie-Features-New-Data-Across-Difficult-to-Treat-Solid-Tumors-and-Blood-Cancers-at-ASCO-2025,-Highlighting-Breadth-and-Depth-of-its-Oncology-Portfolio

[Solsen]

Genmab arbejder med samme indikationer med acasunlimab og nok mere sammenligneligt med deres ADC stof fra Profound - GEN1286